Cited by 234Cancer-related Molecular PathwaysUbiquitin and proteasome pathwaysHeat shock proteins research

The DOI matches its Crossref record; 94 of the 95 references it cites were found in a registry or an index.

MDMX: from bench to bedside

Open access

Marine, Jean-Christophe W., Dyer, Michael A., Jochemsen, Aart G.·2007·Journal of Cell Science

Open this paper in CoChat — free account Open PDF

Abstract

The tumor suppressor protein p53 is negatively regulated by Mdm2, a ubiquitin ligase protein that targets p53 for degradation. Mdmx (also known as Mdm4) is a relative of Mdm2 that was identified on the basis of its ability to physically interact with p53. An increasing body of evidence, including recent genetic studies, suggests that Mdmx also acts as a key negative regulator of p53. Aberrant expression of MDMX could thus contribute to tumor formation. Indeed, MDMX amplification and/or overexpression occurs in several diverse tumors. Strikingly, recent work identifies MDMX as a specific chemotherapeutic target for treatment of retinoblastoma. Specific MDMX antagonists should therefore be developed as a tool to ensure activation of `dormant' p53 activity in tumors that retain wild-type p53.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1242/jcs.03362

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“Mdm2 is a RING-finger-containing protein that acts as an E3 ligase, which is essential for ubiquitylation and subsequent degradation of p53 (Haupt et al., 1997; Kubbutat et al., 1997).”
Background
Live or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 1×
“Mdm2-deficient mice die very early in development prior to implantation, whereas mice lacking both p53 and Mdm2 are viable and indistinguishable from mice lacking only p53 (Montes de Oca Luna et al., 1995; Jones et al., 1995).”
Background

Flagged first, then by citations

Show all 95 references

1 of the 95 references couldn’t be matched to a known paper.

Sorted by citations

Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Mutant p53: one name, many proteinsPreprint
Freed-Pastor, W. A., & Prives, C. L. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,290
Linking the p53 tumour suppressor pathway to somatic cell reprogramming
Kawamura, T., Suzuki, J., Wang, Y. V., Menendez, S., Morera, L. B., Raya, A., Wahl, G. M., & Belmonte, J. C. I. (2009) · Nature · doi:10.1038/nature08311 · Cited by 1,115
Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy
Chang, Y. S., Graves, B. J., Guerlavais, V., Tovar, C., Packman, K. E., To, K.-H., Olson, K. A., Kesavan, K. P., Gangurde, P., Mukherjee, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303002110 · Cited by 681
p53 post-translational modification: deregulated in tumorigenesis
Dai, C., & Gu, W. J. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.09.002 · Cited by 545
Posttranslational Modification of p53: Cooperative Integrators of FunctionPreprint
Meek, D. W., & Anderson, C. W. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000950 · Cited by 510
The p53 orchestra: Mdm2 and Mdmx set the tone
Wade, M., Wang, Y. V., & Wahl, G. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.01.009 · Cited by 450
Regulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX
Pazgier, M., Liu, M., Zou, G., Yuan, W., Li, C., Li, C., Li, J., Monbo, J., Zella, D., Tarasov, S. G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900947106 · Cited by 391
p53 at a glance
Brady, C. A., & Attardi, L. D. (2010) · Journal of Cell Science · doi:10.1242/jcs.064501 · Cited by 400
Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm
Soussi, T., & Wiman, K. G. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.001 · Cited by 375
Mdm2-mediated ubiquitylation: p53 and beyond
Marine, J.-C., & Lozano, G. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.68 · Cited by 354
Self-citation
The Tumor Suppressor p53: From Structures to Drug DiscoveryPreprint
Joerger, A. C., & Fersht, A. R. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000919 · Cited by 380
The Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
Manfredi, J. J. (2010) · Genes & Development · doi:10.1101/gad.1941710 · Cited by 344
MDM4 is a key therapeutic target in cutaneous melanoma
Gembarska, A., Luciani, F., Fedele, C., Russell, E. A., Dewaele, M., Villar, S., Zwolinska, A., Haupt, S., de Lange, J., Yip, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2863 · Cited by 327
Self-citation
Regulation of the p53 response and its relationship to cancer
Meek, D. W. (2015) · Biochemical Journal · doi:10.1042/bj20150517 · Cited by 311
Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans
Linke, K., Mace, P. D., Smith, C. A., Vaux, D. L., Silke, J., & Day, C. L. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402309 · Cited by 288
A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
Bernal, F., Wade, M. R., Godes, M., Davis, T. N., Whitehead, D. G., Kung, A. L., Wahl, G. M., & Walensky, L. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.024 · Cited by 288
MDM2 and MDM4: p53 regulators as targets in anticancer therapy
Toledo, F., & Wahl, G. M. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.03.022 · Cited by 261
ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis
Shi, Y., Nikulenkov, F., Zawacka‐Pankau, J., Li, H., Gabdoulline, R. R., Xu, J., Eriksson, S. E., Hedström, E., Issaeva, N., Kel, A. E., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2013.186 · Cited by 236
Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery
Popowicz, G. M., Czarna, A., Wolf, S., Wang, K., Wang, W., Dömling, A. S. S., & Holak, T. A. (2010) · Cell Cycle · doi:10.4161/cc.9.6.10956 · Cited by 232
D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms
Liu, M., Li, C., Pazgier, M., Li, C., Mao, Y., Lv, Y., Gu, B., Wei, G., Yuan, W., Zhan, C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008930107 · Cited by 236
Ribosomal Protein S7 Is Both a Regulator and a Substrate of MDM2
Zhu, Y. Y., Poyurovsky, M. V., Li, Y., Biderman, L., Stahl, J., Jacq, X., & Prives, C. L. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.07.014 · Cited by 206
Identification and Characterization of the First Small Molecule Inhibitor of MDMX
Reed, D., Shen, Y., Shelat, A. A., Arnold, L. A., Ferreira, A. M., Zhu, F., Mills, N., Smithson, D. C., Regni, C. A., Bashford, D., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.056747 · Cited by 198
Self-citation
The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo
Huang, L., Yan, Z., Liao, X., Li, Y., Yang, J., Wang, Z.-G., Zuo, Y., Kawai, H., Shadfan, M., Ganapathy, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102309108 · Cited by 193
An Illegitimate microRNA Target Site within the 3′ UTR of MDM4 Affects Ovarian Cancer Progression and Chemosensitivity
Wynendaele, J., Böhnke, A., Leucci, E., Nielsen, S. J., Lambertz, I., Hammer, S., Sbrzesny, N., Kubitza, D., Wolf, A. A., Gradhand, E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0527 · Cited by 171
Self-citation
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170
The Structure‐Based Design of Mdm2/Mdmx–p53 Inhibitors Gets Serious
Popowicz, G. M., Dömling, A. S. S., & Holak, T. A. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201003863 · Cited by 170
Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis in vivo
Lambertz, I. U., Nittner, D., Mestdagh, P., Denecker, G., Vandesompele, J., Dyer, M. A., & Marine, J. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.202 · Cited by 161
Self-citation
Systematic Mutational Analysis of Peptide Inhibition of the p53–MDM2/MDMX Interactions
Li, C. V., Pazgier, M., Li, C., Yuan, W., Liu, M., Wei, G., Lu, W., & Lu, W. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.03.005 · Cited by 149
Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability
Pant, V., Xiong, S., Iwakuma, T., Quintás-Cardama, A., & Lozano, G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102241108 · Cited by 134
Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives as Novel Inhibitors of p53–MDM2 Protein–Protein Interaction
Zhuang, C., Miao, Z., Zhu, L., Dong, G., Guo, Z., Wang, S., Zhang, Y., Wu, Y., Yao, J., Sheng, C., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300969t · Cited by 131
Molecular Basis for the Inhibition of p53 by Mdmx
Popowicz, G. M., Czarna, A., Rothweiler, U., Szwagierczak, A., Krajewski, M., Weber, L., & Holak, T. A. (2007) · Cell Cycle · doi:10.4161/cc.6.19.4740 · Cited by 131
Small molecular weight protein–protein interaction antagonists—an insurmountable challenge?
Dömling, A. S. S. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.04.603 · Cited by 128
Novel Pyrrolopyrimidine-Based α-Helix Mimetics: Cell-Permeable Inhibitors of Protein−Protein Interactions
Lee, J. H., Zhang, Q., Jo, S., Chai, S. C., Oh, M., Im, W., Lu, H., & Lim, H. (2010) · Journal of the American Chemical Society · doi:10.1021/ja108230s · Cited by 126
Dissenting degradation: Deubiquitinases in cell cycle and cancer
Bonacci, T., & Emanuele, M. J. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.008 · Cited by 128
A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis
Wang, H., Ma, X., Ren, S., Buolamwini, J. K., & Yan, C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0581 · Cited by 117
Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway
Hu, W., Feng, Z., Modica, I., Klimstra, D. S., Song, L., Allen, P. J., Brennan, M. F., Levine, A. J., & Tang, L. H. (2010) · Genes & Cancer · doi:10.1177/1947601910371979 · Cited by 115
A Left‐Handed Solution to Peptide Inhibition of the p53–MDM2 Interaction
Liu, M., Pazgier, M., Li, C., Yuan, W., Li, C., & Lu, W. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201000329 · Cited by 115
MALAT1: A key regulator in lung cancer pathogenesis and therapeutic targeting
Bhat, A. A., Afzal, O., Afzal, M., Gupta, G., Thapa, R., Ali, H., Almalki, W. H., Kazmi, I. A., Alzarea, S. I., Saleem, S., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154991 · Cited by 111
Identification of ribosomal protein S25 (RPS25)–MDM2–p53 regulatory feedback loop
Zhang, X., Wang, W., Wang, H., Wang, M.-H., Xu, W., & Zhang, R. (2012) · Oncogene · doi:10.1038/onc.2012.289 · Cited by 106
A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity
Yan, S., Yan, J., Liu, D., Li, X., Kang, Q., You, W., Zhang, J., Wang, L., Tian, Z., Lu, W., et al. (2021) · Theranostics · doi:10.7150/thno.59020 · Cited by 108
Discovery of Mdm2-MdmX E3 Ligase Inhibitors Using a Cell-Based Ubiquitination Assay
Herman, A. G., Hayano, M., Poyurovsky, M. V., Shimada, K., Skouta, R., Prives, C., & Stockwell, B. R. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0104 · Cited by 100
MdmX is a substrate for the deubiquitinating enzyme USP2a
Allende-Vega, N., Sparks, A., Lane, D. P., & Saville, M. K. (2010) · Oncogene · doi:10.1038/onc.2009.330 · Cited by 100
New Insights in Thyroid Cancer and p53 Family Proteins
Manzella, L., Stella, S., Pennisi, M. S., Tirrò, E., Massimino, M., Romano, C., Puma, A., Tavarelli, M., & Vigneri, P. G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061325 · Cited by 99
p53 is activated in response to disruption of the pre-mRNA splicing machinery
Allende-Vega, N., Dayal, S., Agarwala, U., Sparks, A., Bourdon, J., & Saville, M. K. (2012) · Oncogene · doi:10.1038/onc.2012.38 · Cited by 98
Melatonin down‐regulates MDM 2 gene expression and enhances p53 acetylation in MCF ‐7 cells
Proietti, S., Cucina, A., Dobrowolny, G., D’Anselmi, F., Dinicola, S., Masiello, M. G., Pasqualato, A., Palombo, A., Morini, V., Reiter, R. J., et al. (2014) · Journal of Pineal Research · doi:10.1111/jpi.12150 · Cited by 99
Structure of human MDM2 complexed with RPL11 reveals the molecular basis of p53 activationPreprint
Zheng, J., Lang, Y., Zhang, Q., Cui, D., Sun, H., Jiang, L., Chen, Z., Zhang, R., Gao, Y., Tian, W., et al. (2015) · Genes & Development · doi:10.1101/gad.261792.115 · Cited by 94
Small molecule agents targeting the p53‐MDM2 pathway for cancer therapy
Wang, W., & Hu, Y. (2011) · Medicinal Research Reviews · doi:10.1002/med.20236 · Cited by 87
Validation of MdmX as a therapeutic target for reactivating p53 in tumors
Garcia, D., Warr, M. R., Martins, C. P., Brown Swigart, L., Passegué, E., & Evan, G. I. (2011) · Genes & Development · doi:10.1101/gad.16722111 · Cited by 83
The role of MDM2 and MDM4 in breast cancer development and prevention
Haupt, S., Vijayakumaran, R., Miranda, P. J., Burgess, A., Lim, E., & Haupt, Y. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx007 · Cited by 83
An Ultrahigh Affinity d -Peptide Antagonist Of MDM2
Zhan, C., Zhao, L., Wei, X., Wu, X., Chen, X., Yuan, W., Lu, W., Pazgier, M., & Lu, W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3005465 · Cited by 80
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53‐mediated intrinsic‐apoptotic pathway
Mancini, F., Conza, G. D., Pellegrino, M., Rinaldo, C., Prodosmo, A., Giglio, S., D’Agnano, I., Florenzano, F., Felicioni, L., Buttitta, F., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.154 · Cited by 82
Increased Radioresistance and Accelerated B Cell Lymphomas in Mice with Mdmx Mutations that Prevent Modifications by DNA-Damage-Activated Kinases
Wang, Y. V., Leblanc, M., Wade, M., Jochemsen, A. G., & Wahl, G. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.05.008 · Cited by 79
Self-citation
Limitations of Peptide Retro-inverso Isomerization in Molecular Mimicry
Li, C., Pazgier, M., Li, J., Li, C., Liu, M., Zou, G., Li, Z., Chen, J., Tarasov, S. G., Lu, W., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.116814 · Cited by 79
Apamin as a Template for Structure‐Based Rational Design of Potent Peptide Activators of p53
Li, C., Pazgier, M., Liu, M., Lu, W., & Lu, W. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200904550 · Cited by 81
The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy
Clancy, A. A., Spaans, J. N., & Weberpals, J. I. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw242 · Cited by 76
The regulation of MDM2 by multisite phosphorylation—opportunities for molecular-based intervention to target tumours?
Meek, D. W., & Hupp, T. R. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.005 · Cited by 76
Turning a Scorpion Toxin into an Antitumor Miniprotein
Li, C., Liu, M., Monbo, J., Zou, G., Li, C., Yuan, W., Zella, D., Lu, W., & Lu, W. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8042036 · Cited by 75
Targeting RNA polymerase I to treat MYC-driven cancer
Poortinga, G., Quinn, L. M., & Hannan, R. D. (2014) · Oncogene · doi:10.1038/onc.2014.13 · Cited by 74
Mycoplasmas–Host Interaction: Mechanisms of Inflammation and Association with Cellular Transformation
Benedetti, F., Curreli, S., & Zella, D. (2020) · Microorganisms · doi:10.3390/microorganisms8091351 · Cited by 80
Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes
Kallen, J. A., Goepfert, A., Blechschmidt, A., Izaac, A., Geiser, M., Tavares, G., Ramage, P., Furet, P., Masuya, K., & Lisztwan, J. H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809096200 · Cited by 75
Mdmx promotes genomic instability independent of p53 and Mdm2
Carrillo, A. M., Bouska, A., Arrate, M. P., & Eischen, C. M. (2015) · Oncogene · doi:10.1038/onc.2014.27 · Cited by 69
The p53-MDM2/MDMX axis – A chemotype perspective
Khoury, K., Popowicz, G. M., Holak, T. A., & Dömling, A. S. S. (2011) · MedChemComm · doi:10.1039/c0md00248h · Cited by 71
Inhibition of p53 DNA Binding Function by the MDM2 Protein Acidic Domain
Cross, B. L., Chen, L., Cheng, Q., Li, B., Yuan, Z.-M., & Chen, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.228981 · Cited by 72
PML enhances the regulation of p53 by CK1 in response to DNA damage
Alsheich-Bartok, O., Haupt, S., Snir-Alkalay, I., Saito, S., Appella, E., & Haupt, Y. (2008) · Oncogene · doi:10.1038/sj.onc.1211036 · Cited by 71
c-Abl Phosphorylates Hdmx and Regulates Its Interaction with p53
Zuckerman, V., Lenos, K., Popowicz, G. M., Silberman, I., Grossman, T., Marine, J.-C., Holak, T. A., Jochemsen, A. G., & Haupt, Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809211200 · Cited by 68
Self-citation
Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations
Yu, Q., Li, Y., Mu, K., Li, Z., Meng, Q., Wu, X., Wang, Y., & Li, L. (2014) · Diagnostic Pathology · doi:10.1186/1746-1596-9-71 · Cited by 67
Ensemble-based virtual screening reveals dual-inhibitors for the p53–MDM2/MDMX interactions
Barakat, K., Mane, J. Y., Friesen, D. E., & Tuszyński, J. A. (2009) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2009.12.003 · Cited by 61
A p53-dependent translational program directs tissue-selective phenotypes in a model of ribosomopathies
Tiu, G. C., Kerr, C. H., Forester, C. M., Krishnarao, P. S., Rosenblatt, H. D., Raj, N., Lantz, T. C., Zhulyn, O., Bowen, M. E., Shokat, L., et al. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.06.013 · Cited by 59
Classification of food vegetable oils by fluorimetry and artificial neural networks
da Silva, C. E. T., Filardi, V. L., Pepe, I. M., Chaves, M. A., & Santos, C. M. S. (2014) · Food Control · doi:10.1016/j.foodcont.2014.06.030 · Cited by 59
On the Mechanism of Action of SJ-172550 in Inhibiting the Interaction of MDM4 and p53
Bista, M., Smithson, D., Pecak, A., Salinas, G., Pustelny, K., Min, J., Pirog, A., Finch, K., Zdzalik, M., Waddell, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037518 · Cited by 58
Self-citation
The p53-mediated cytotoxicity of photodynamic therapy of cancer: Recent advances
Zawacka‐Pankau, J., Krachulec, J., Grulkowski, I., Bielawski, K. P., & Selivanova, G. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.07.012 · Cited by 62
Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin‐3 in gastric cancer cells
Endo, S., Yamato, K., Hirai, S., Moriwaki, T., Fukuda, K., Suzuki, H., Abei, M., Nakagawa, I., & Hyodo, I. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01821.x · Cited by 61
P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition
Najem, A., Krayem, M., Salès, F., Hussein, N., Badran, B. M., Robert, C., Awada, A. H., Journé, F., & Ghanem, G. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.033 · Cited by 57
MdmX Promotes Bipolar Mitosis To Suppress Transformation and Tumorigenesis in p53-Deficient Cells and Mice
Matijasevic, Z., Steinman, H. A., Hoover, K., & Jones, S. N. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01108-07 · Cited by 58
Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
DeVine, T., & Dai, M. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319180009 · Cited by 58
Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties
Prodosmo, A., Giglio, S., Moretti, S., Mancini, F., Barbi, F., Avenia, N., Conza, G. D., Schünemann, H. J., Pistola, L., Ludovini, V., et al. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0322-6 · Cited by 56
Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer
Koster, R., van Vugt, M. A. T. M., Timmer‐Bosscha, H., Gietema, J. A., & de Jong, S. (2013) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2013.13 · Cited by 58
Puma Deletion Delays Cardiac Dysfunction in Murine Heart Failure Models Through Attenuation of Apoptosis
Mandl, A., Pham, L. H., Tóth, K., Zambetti, G., & Erhardt, P. (2011) · Circulation · doi:10.1161/circulationaha.110.988303 · Cited by 57
p53 ubiquitination by Mdm2: A never ending tail?
Coutts, A. S., Adams, C., & Thangue, N. B. L. (2009) · DNA repair · doi:10.1016/j.dnarep.2009.01.008 · Cited by 56
Using Mice to Examine p53 Functions in Cancer, Aging, and LongevityPreprint
Donehower, L. A. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001081 · Cited by 59
Genetic and Epigenetic Discoveries in Human Retinoblastoma
McEvoy, J. D., & Dyer, M. A. (2015) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2015013711 · Cited by 54
Self-citation
A single synonymous mutation determines the phosphorylation and stability of the nascent protein
Karakostis, K., Gnanasundram, S. V., López, I., Thermou, A., Wang, L., Nylander, K., Olivares‐Illana, V., & Fåhræus, R. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy049 · Cited by 54
The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours
Pipinikas, C., Berner, A., Sposito, T., & Thirlwell, C. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0175 · Cited by 52
Targeting the ubiquitin–proteasome system to activate wild-type p53 for cancer therapy
Allende-Vega, N., & Saville, M. K. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.004 · Cited by 51
The Proapoptotic C16-ceramide-Dependent Pathway Requires the Death-Promoting Factor Btf in Colon Adenocarcinoma Cells
Renert, A.-F., Leprince, P., Dieu, M., Renaut, J., Raes, M. J., Bours, V., Chapelle, J.-P., Piette, J. G., Merville, M.-P., & Fillet, M. (2009) · Journal of Proteome Research · doi:10.1021/pr9005316 · Cited by 51
A Critical Role for Noncoding 5S rRNA in Regulating Mdmx Stability
Li, M., & Gu, W. J. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.020 · Cited by 54
HIF-2α mediates hypoxia-induced LIF expression in human colorectal cancer cells
Wu, L., Yu, H., Zhao, Y., Zhang, C., Wang, J., Yue, X., Yang, Q., & Hu, W. (2015) · Oncotarget · doi:10.18632/oncotarget.3017 · Cited by 49
Structure of full‐length p53 tumor suppressor probed by chemical cross‐linking and mass spectrometry
Arlt, C., Ihling, C. H., & Sinz, A. (2015) · PROTEOMICS · doi:10.1002/pmic.201400549 · Cited by 48
Interrogation of MDM2 Phosphorylation in p53 Activation Using Native Chemical Ligation: The Functional Role of Ser17 Phosphorylation in MDM2 Reexamined
Zhan, C., Varney, K. M., Yuan, W., Zhao, L., & Lu, W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja301255n · Cited by 50
Recent Advances in Validating MDM2 as a Cancer Target
Rayburn, E. R., Ezell, S. J., & Zhang, R. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009789124628 · Cited by 50
An Update on MDMX and Dual MDM2/X Inhibitors
Espadinha, M., Barcherini, V., Lopes, E. A., & Santos, M. M. M. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180604080119 · Cited by 49
Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner
Esfandiari, A., Hawthorne, T. A., Nakjang, S., & Lunec, J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0651 · Cited by 49
Lessons from Retinoblastoma: Implications for Cancer, Development, Evolution, and Regenerative Medicine
Dyer, M. A. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.07.010 · Cited by 48
Self-citation
Role of Mdm2 and Mdmx in DNA repair
Eischen, C. M. (2016) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw052 · Cited by 45
Mdm2 and Tumorigenesis: Evolving Theories and Unsolved Mysteries
Senturk, E., & Manfredi, J. J. (2012) · Genes & Cancer · doi:10.1177/1947601912457368 · Cited by 46
Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy
Song, Y., Dong, Q., Ni, Y.-K., Xu, X., Chen, C.-X., & Chen, W. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s448684 · Cited by 47
Targeting mechanosensitive MDM4 promotes lung fibrosis resolution in aged mice
Qu, J., Yang, S., Zhu, Y., Guo, T., Thannickal, V. J., & Zhou, Y. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202033 · Cited by 45
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance
Chen, L., & Tweddle, D. A. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00173 · Cited by 43

Authors: Marine, J.-C. W., Dyer, M. A., & Jochemsen, A. G.
Affiliations: Vlaams Instituut voor Biotechnologie (BE)
St. Jude Children's Research Hospital (US)
Leiden University Medical Center (NL)
Corresponding author: Marine, Jean-Christophe W.
ORCID: Marine, Jean-Christophe W.
Dyer, Michael A.
Jochemsen, Aart G.
Venue: Journal of Cell Science
Publisher: The Company of Biologists
Published: 2007-02-01
Volume: 120
Issue: 3
Pages: 371-378
ISSN: 0021-9533 (ISSN-L)
1477-9137
DOI: 10.1242/jcs.03362
OpenAlex: W2141224144
Cited by: 228
References: 95
Citations by year: 2026: 2 · 2025: 1 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 8 · 2020: 10 · 2019: 2 · 2018: 8 · 2017: 6 · 2016: 12 · 2015: 10 · 2014: 18 · 2013: 14 · 2012: 21
FWCI: 2.78
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Cell Science (publishedVersion)
PubMed (publishedVersion)
Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords: MDMX, MDM2, p53, tumor suppressor regulation, ubiquitin ligase, retinoblastoma, chemotherapeutic target, wild-type p53
MeSH terms: Animals, Humans, Models, Biological, Neoplasms, Nuclear Proteins, Proto-Oncogene Proteins, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Cell Cycle Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MDMX: from bench to bedside

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks